Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

A bigger footprint for Rubius Therapeutics
September 2018
SHARING OPTIONS:

CAMBRIDGE, Mass.—Biotechnology company Rubius Therapeutics Inc. recently inked a purchase and sale agreement for a 135,000-square-foot manufacturing facility in Smithfield, R.I. Rubius intends to invest up to $95 million in this property through 2020, and up to $155 million in total over more than five years, with plans to hire roughly 150 employees for the new site. The deal is slated to close in Q3 2018. With this new space, Rubius will be able to scale up its manufacturing to produce large quantities of its Red Cell Therapeutic product candidates and the lentiviral vectors necessary for encoding biotherapeutic proteins inside or on the surface of each candidate. Rubius intends to customize the new facility into multiple manufacturing suites to allow for cGMP compliance for clinical supply and potentially commercial supply of Red Cell Therapeutic products.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.